Cellectar Biosciences(CLRB) - 2025 Q4 - Annual Results

Exhibit 99.1 Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHA ...